Abstract Number: 1201 • ACR Convergence 2020
Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials
Background/Purpose: RA patients (pts) often suffer substantial pain despite ongoing treatment (tx) and regard pain control as a top tx goal. Filgotinib (FIL)—a potent, oral…Abstract Number: 1217 • ACR Convergence 2020
Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells
Background/Purpose: Janus kinase (JAK) family is comprised of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). JAKs form homo- or hetero-complexes, the combination of which…Abstract Number: 1235 • ACR Convergence 2020
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of…Abstract Number: 1456 • ACR Convergence 2020
Exploring the RA Bone Marrow Niche by Single-cell Technology to Identify Long Lived ACPA+ Plasma Cells
Background/Purpose: Autoantibodies is a hallmark of rheumatoid arthritis, placing the adaptive immune system and B-cells centrally in the pathogenesis. The anti-citrullinated autoantibodies (ACPA) detected in…Abstract Number: 1534 • ACR Convergence 2020
Combined Thermal and Ultrasound Imaging in Rheumatoid Arthritis Is Superior to Either Imaging Alone in Terms of Correlation with the 28-joint Disease Activity Score
Background/Purpose: Combined thermal and ultrasound (US) imaging modalities in detecting joint inflammation in rheumatoid arthritis (RA) has not been evaluated relative to thermal or US…Abstract Number: 1597 • ACR Convergence 2020
Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
Background/Purpose: Rheumatoid Arthritis (RA) management guidelines recommend the collection of Disease Activity Measures (DAMs) to direct therapy as a component of a “treat-to-target” (T2T) strategy. …Abstract Number: 1720 • ACR Convergence 2020
Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
Background/Purpose: Individuals at high-risk for future rheumatoid arthritis (RA) may be identified by screening for circulating RA-related autoantibodies including antibodies to citrullinated protein antigens (ACPA).…Abstract Number: 1736 • ACR Convergence 2020
Health Assessment Questionnaire Predicts All-Cause Mortality at One Year in Patients with Early Rheumatoid Arthritis
Background/Purpose: Patients with RA are at greater risk of mortality than the general population. Higher HAQ disability has been associated with hospitalizations and mortality in…Abstract Number: 1754 • ACR Convergence 2020
The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study
Background/Purpose: Despite the advances in treatment of rheumatoid arthritis (RA), many patients do not achieve remission or full physical functioning. We have previously shown that…Abstract Number: 1785 • ACR Convergence 2020
Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases
Background/Purpose: The importance of safe and effective contraception for women with rheumatic diseases has been increasing. Several studies have demonstrated that carefully planned pregnancies are…Abstract Number: 1996 • ACR Convergence 2020
Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study
Background/Purpose: Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to…Abstract Number: 2043 • ACR Convergence 2020
Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis
Background/Purpose: Citrulline (cit) autoimmunity is central in rheumatoid arthritis (RA), including both anti-citrulline protein antibodies (ACPA) and autoreactive CD4+ T cells. While the ACPA are…Abstract Number: 0046 • ACR Convergence 2020
Socioeconomic Disparities in Functional Status Among RA Patients: A Longitudinal Analysis Using RISE Data
Background/Purpose: Prior studies have shown that RA outcomes, including disease activity, erosions, and disability, are worse among patients with low socioeconomic status (SES). However, few…Abstract Number: 0135 • ACR Convergence 2020
Understanding the Rheumatologist-Patient Relationship in Treating Rheumatoid Arthritis
Background/Purpose: Understanding patient satisfaction with their rheumatologist and the drivers of satisfaction is crucial to improving doctor-patient interactions, helping patients get on the right treatment…Abstract Number: 0160 • ACR Convergence 2020
Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
Background/Purpose: The Patient-Reported Outcome Measure Information System (PROMIS) includes a set of instruments developed to measure physical, mental and social health. PROMIS measures have been…
- « Previous Page
- 1
- …
- 157
- 158
- 159
- 160
- 161
- …
- 188
- Next Page »